Keros Therapeutics (NASDAQ:KROS) and ZyVersa Therapeutics (NASDAQ:ZVSA) Financial Contrast

Keros Therapeutics (NASDAQ:KROS) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.

Profitability

This table compares Keros Therapeutics and ZyVersa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-27,890.94%	-41.74%	-38.42%
ZyVersa Therapeutics	N/A	-224.85%	-103.22%

Risk & Volatility

Keros Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Valuation and Earnings

This table compares Keros Therapeutics and ZyVersa Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$3.55 million	123.29	-$152.99 million	($5.01)	-2.15
ZyVersa Therapeutics	N/A	N/A	-$98.30 million	N/A	N/A

ZyVersa Therapeutics has lower revenue, but higher earnings than Keros Therapeutics.

Insider and Institutional Ownership

71.6% of Keros Therapeutics shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 22.9% of Keros Therapeutics shares are held by insiders. Comparatively, 0.3% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Keros Therapeutics and ZyVersa Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	0	6	8	0	2.57
ZyVersa Therapeutics	0	0	0	0	0.00

Keros Therapeutics presently has a consensus price target of $42.33, suggesting a potential upside of 292.34%. Given Keros Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Keros Therapeutics is more favorable than ZyVersa Therapeutics.

Summary

Keros Therapeutics beats ZyVersa Therapeutics on 9 of the 11 factors compared between the two stocks.

About Keros Therapeutics

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.